Overview
Choose your reading level:
In plain language
Semaglutide is a GLP-1 receptor agonist used in approved medicines. It affects appetite and blood-glucose regulation; the approved uses depend on the product, formulation and patient group. (FDA Wegovy label, June 2026)
Wegovy is available as an injection and a tablet. Their approved populations and indications are not identical, so results or permissions for one formulation should not be assumed to apply to all semaglutide products. (FDA Wegovy label, June 2026)
Common adverse effects include nausea and other gastrointestinal symptoms. The label also contains serious warnings; this educational summary is not a complete safety assessment or treatment guide. (FDA Wegovy label, June 2026)
For students
Semaglutide is a modified GLP-1 analogue. Compared with human GLP-1, its design includes Aib8 and Arg34 substitutions and derivatization at Lys26; the lipid-containing side chain supports albumin binding and prolonged exposure. (Lau et al., 2015)
The FDA label describes a C18 fatty diacid linked through a spacer at Lys26 and an elimination half-life of approximately one week. The molecular formula is C₁₈₇H₂₉₁N₄₅O₅₉ and the molecular mass is 4,113.58 g/mol. (FDA Wegovy label, June 2026)
The drug activates the GLP-1 receptor. Its appetite, glucose-regulatory and gastric-emptying effects do not mean every patient or formulation has the same outcomes. (FDA Wegovy label, June 2026)
For researchers and instructors
Weight-management example. In the 68-week adult injection study reported in the FDA label, mean body-weight change was −14.9% with semaglutide versus −2.4% with placebo. Participants had obesity, or overweight with a weight-related condition; type 2 diabetes was excluded. This is a defined trial result, not an expected outcome for every user. (FDA Wegovy label, June 2026)
Cardiovascular example. SELECT randomized 17,604 adults with established cardiovascular disease and overweight or obesity, without diabetes. Major cardiovascular events occurred in 6.5% of the injection group versus 8.0% of the placebo group; hazard ratio 0.80 (95% CI 0.72–0.90). (FDA Wegovy label, June 2026)
Safety boundaries. The boxed warning concerns thyroid C-cell tumors observed in rodents; whether semaglutide causes these tumors in humans is unknown. Other label warnings include pancreatitis, gallbladder disease, severe gastrointestinal reactions and diabetic-retinopathy complications. Consult the complete current product label rather than this non-exhaustive summary. (FDA Wegovy label, June 2026)
Molecular identity
- Amino acids
- 31 (modified)
- Molecular weight
- ~4,113.6 Da
- Formula
- C₁₈₇H₂₉₁N₄₅O₅₉
- Sequence
- Modified GLP-1(7–37) analogue with Aib8, Arg34 and a C18 fatty diacid chain on Lys26
Origin and history
GLP-1-based drug development built on work by Joel Habener, Svetlana Mojsov, Lotte Bjerre Knudsen and other researchers. The 2024 Lasker award recognized their discovery and therapeutic-development contributions. (Lasker Foundation: 2024 award)
Lau and colleagues published the design of semaglutide in 2015. The later FDA label documents approved Wegovy formulations and uses; Novo Nordisk reported the US oral Wegovy approval on December 22, 2025. That announcement establishes what the sponsor reported, not independent validation of clinical benefit. (Lau et al., 2015) (FDA Wegovy label, June 2026) (Novo Nordisk approval announcement, December 2025)
Human evidence
Controlled human evidence supports specific approved indications, not every proposed use. The injection weight-management study and SELECT assessed different populations and outcomes; the FDA label describes the relevant formulations and limitations. (FDA Wegovy label, June 2026)
Safety and regulatory status
Approval is product- and indication-specific. The current linked label distinguishes Wegovy injection and tablets; it does not validate online products sold as “research semaglutide”. This profile provides no dosing or sourcing guidance. (FDA Wegovy label, June 2026)
Editorial update · November 9, 2026
Replaced broad evidence summaries with formulation- and population-specific examples, clarified the rodent thyroid warning and removed an unverified molecular illustration. This was an editorial source check, not independent expert review.
Sources
- FDA Wegovy label, June 2026https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s007lbl.pdf
- Lau et al., 2015https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b00726
- Lasker Foundation: 2024 awardhttps://laskerfoundation.org/winners/glp-1-based-therapy-for-obesity/
- Novo Nordisk approval announcement, December 2025https://www.novonordisk-us.com/media/press-releases/wegovy-pill-fda-approval-obesity.html
Hernandez Gener, E. (2026, November 9). Semaglutide: molecular data, research history and evidence. VALREXA Biosciences. https://valrexa.com/peptides/semaglutide.html
APA style · Editorially updated November 9, 2026 · Our editorial standardsEditorially updated November 9, 2026. Trial and regulatory status can change; confirm in the linked registries. This profile is educational and is not medical advice, a treatment recommendation, or dosing or sourcing guidance. Report an error · Corrections policy